Bio€quity hosts Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. Ilya Pharma will share milestones and data from the clinical developments and the emerging pipeline.
Patent covers treatment of cutaneous human and animal wounds using transformed lactic acid bacteria
Bloomberg reports: EU will become shareholder in startups for the first time.
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.
FDA opened for 5 new endpoints in Nov 2020 (vs. only 1 until then) following thorough work by FDA’s Inter-center Wound Healing Work group and industry Wound Experts/FDA Clinical Endpoints Project.